CyGene Laboratories and LabSafe Sign Distribution Agreement for Genetic Testing Products and Services

CyGene Laboratories and LabSafe Sign Distribution Agreement for Genetic Testing Products and Services
6/27/2006 10:58:00 AM EST
BIOWIRE
CyGene Laboratories, Inc. (OTC:CYGE), an emerging leader in direct-to-consumer genetic testing services, has signed a product distribution agreement with LabSafe LLC, one of the nation's largest online e-commerce laboratory screening test providers. Through this distribution agreement, the two companies have established a strategic business relationship to deliver genetic testing products and services via e-commerce.
"The relationship between CyGene and LabSafe is very synergistic," said Martin Munzer, CyGene's president and CEO. "LabSafe has a well-established distribution system that is a great fit with our product line and our patent-pending product distribution business model."
Brian Lunn, LabSafe's president and CEO, added, "The market for predictive genomic testing is poised for tremendous growth. We are pleased to partner with CyGene Laboratories to distribute the company's innovative products and services. We look forward to serving this rapidly-expanding market together."
About CyGeneDIRECT
CyGeneDIRECT is an online consumer website that provides individuals with education and the opportunity to decide whether genetic testing is right for them. Individuals are able to purchase genetic test kits from a third party fulfillment center and retrieve their results anonymously in a comprehensive personalized report available on a secure server. The reports help them to understand how their personal genetics affect certain risks, how other factors contribute in combination with their genetic profile, and how to modify these factors to decrease their risk. For more information on CyGeneDIRECT, please visit http://www.cygenedirect.com.

For more information on LabSafe, please visit http://www.labsafe.com/

About CyGene Laboratories, Inc.
CyGene Laboratories Inc., based in Coral Springs, Florida, is a biotechnology company focused on commercializing genetic and diagnostic testing, as well as developing therapies for infectious, genetic and autoimmune diseases. CyGene's scientific base rests on its Haystack Processing technologies, which it has been developing since 1995. As a result of its work on Haystack Processing, the Company has achieved significant technological breakthroughs that have led to the discovery of its other platform technologies. CyGene believes its patented technologies have promise in the discovery, development and utilization of cutting edge diagnostics based on synthetic DNA and therapeutics based on the rapid clearance of pathogens from the blood.
About LabSafe LLC
LabSafe LLC, based in Hollywood, Florida, is one of the nation's largest direct-to-consumer providers of laboratory products and services. Its mission is to expand access to affordable laboratory tests and to provide laboratory testing consumer education. By providing superior laboratory products and value-added service, LabSafe strives to expand the field of preventative medicine, while assisting in the achievement of population screening testing goals.
Forward-Looking Statements:
The statements made in this news release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Additionally words such as "seek," "intend," "believe," "plan," "estimate," "expect," "anticipate" and other similar expressions are forward-looking statements within the meaning of the Act. Some or all of the results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include, but are not limited to, when or whether the audits of our financial statements will be completed and audit opinions issued, due to unforeseen circumstances or unforeseen issues that may arise during the course of such audits. CyGene Laboratories Inc. has no duty and undertakes no obligation to update such statements. You should independently investigate and fully understand all risks before making investment decisions.